“
TL;DR
A multicenter retrospective cohort study enrolled 49 patients with pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome from five Chinese tertiary centers between January 1, 2012, and July 31, 2018.
Medicine · 11 authors, 7 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
A multicenter retrospective cohort study enrolled 49 patients with pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome from five Chinese tertiary centers between January 1, 2012, and July 31, 2018.
A multicenter retrospective cohort study enrolled 49 patients with pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome from five Chinese tertiary centers between January 1, 2012, and July 31, 2018. The study found a 3-month survival rate of 86%. Patients who survived had lower baseline CTP and SOFA scores and higher rates of anticoagulant use. Long-term survival at 36 months was 76%. The findings suggest anticoagulation is beneficial, particularly for patients with severe disease (CTP class C).